In our cohort, we identified two “TET2-second” patients in the stable cohort with a MPN-phenotype (case 24 and case 28) and four “TET2-first” patients in the progressive cohort with a CMML (case 19), PMF (case 10 and case 12) and MDS/MPN-U (case 15) phenotype. This evidence concerns the gene TET2 and myeloproliferative disorder.